| Popis: |
Tykerb (lapatinib) is a successful medicine for the treatment of a subset of solid tumours driven by aberrant signalling in tumour cells that could be selectively targeted over healthy, normal tissue. The lessons learnt from the discovery and development of lapatinib can serve as a key learning tool in pharmaceutical project management as much as a study in scientific insight. The research team operated without the benefit of protein crystal structure information whilst the knowledge of the ERBB family of biological targets and the required inhibition profile of an effective molecule grew as the project progressed. In brief, because it was a new area of oncology with huge potential for dramatically improved treatments, it was a question of knowing when to be flexible and when to be rigid; of knowing what to change and what to retain. Fundamentals like retaining a strong link between in vitro and in vivo assays were constant throughout the lifetime of the project; progression criteria could be more flexible. Outstanding synthetic design was core to the success of the project, allowing the rapid evaluation of diversely functionalized, high quality small molecules, thus creating a robust drug discovery knowledge base. In the earlier days of the project, the emphasis was on data acquisition and SAR, whereas the success of the selection of GW2016 for clinical study lay in the application of the acquired understanding for the candidate target profile developed throughout the project. |
